In parallel with SGLT2 inhibitors, mitochondrial-targeted antioxidants such as MitoTEMPO and MitoQ effectively prevent AF in preclinical models by quenching mitochondrial ROS—the primary upstream trigger of NLRP3 inflammasome activation. The gene discussed is SLC5A2; the disease is atrial fibrillation.